Phase 1 Lead-in to a Phase 2 Factorial Study of Temozolomide Plus Memantine, Mefloquine, and Metformin as Postradiation Adjuvant Therapy for Newly Diagnosed Glioblastoma

類似資料

• A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients
  著者:: Raizer, J. J., 等
  出版事項: (2016)
• Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma
  著者:: Penas-Prado, Marta, 等
  出版事項: (2015)
• A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma
  著者:: Gilbert, Mark R., 等
  出版事項: (2010)
• Phase 1/1b Study of Lonafarnib and Temozolomide in Patients With Recurrent or Temozolomide Refractory Glioblastoma
  著者:: Yust-Katz, Shlomit, 等
  出版事項: (2013)
• ATNT-20 A PHASE I-II TRIAL EVEROLIMUS AND SORAFENIB IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS: BRAIN TUMOR TREATMENT COLLABORATIVE TRIAL 09-01
  著者:: Raizer, Jeffrey, 等
  出版事項: (2015)